Video Shorts

Molecularly Driven Therapies Drive Ongoing Research in MPNs

1:48

Molecularly Driven Therapies Highlight Ongoing Research in MPNs

4 months ago

John O. Mascarenhas, MD

1:06

Addressing the Need for Cancer Screening in Young Adults

4 months ago

Sonali M. Smith, MD

1:16

Unpacking the Future of AI in Oncology

4 months ago

Alexander T. Pearson, MD, PhD

1:22

MRD as a Surrogate End Point in Multiple Myeloma Trials

4 months ago

Marc J. Braunstein, MD, PhD

0:1.44

How HPV Testing Can Fall Through the Cracks in Cervical Cancer

4 months ago

Dana Chase, MD

2:06

FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma

4 months ago

David A. Braun, MD, PhD

1:04

How Butyrate Loss Affects Post-Transplant Outcomes in Myeloma

5 months ago

Pooja Phull, MD

1:03

Could Zanidatamab Replace Trastuzumab As the Gold Standard in First-Line HER2+ Gastric Cancer?

5 months ago

Manish A. Shah, MD

0:34

Role of Bridging Therapy Before CAR T-Cell Therapy in Myeloma

5 months ago

Matthew J. Frigault, MD

1:34

The Importance of HPV Vaccination in Oncology

5 months ago

Maurie Markman, MD

1:09

The Significance of the FDA Approval of Subcutaneous Daratumumab for Smoldering Multiple Myeloma

5 months ago

Peter Voorhees, MD

Laura Alder, MD, Eric K. Singhi, MD, and Paolo Tarantino, MD, PhD.

2:01

Quick Takes: Bridging the Gaps in Brain Mets, Continued

5 months ago

Paolo Tarantino, MD(+2 more)

0:51

Unpacking Real-World Data in mCRC

5 months ago

Rocio Garcia-Carbonero, MD, PhD

Jason Mouabbi, MD, Manmeet Ahluwalia, MD, MBA, FASCO, Laura Alder, MD.

1:45

Quick Takes: Bridging the Gaps in Brain Mets

5 months ago

Jason Mouabbi, MD(+2 more)

1:58

Lingering Questions on the Earlier Use of Oral SERDs in ER+ Breast Cancer

5 months ago

Seth Wander, MD, PhD

1:02

Dr Singhi on the Emerging Role of TROP2-Directed ADCs in the Evolving Treatment Algorithm of NSCLC

5 months ago

Eric K. Singhi, MD

1:04

Clinical Decision-Making Around Local vs Systemic Therapy for Metastatic Lung Cancer With CNS-Only Disease

5 months ago

Laura Alder, MD

1:10

Patient-Level Clinical Trial Communication Skills For Hematology/Oncology Fellows

5 months ago

Carma L. Bylund, PhD

1:52

ASCO GI 2026 Highlights

5 months ago

0:45

The Use of Measurements in Oncology to Define Clinical Utility

5 months ago

Maurie Markman, MD

0:57

FDA Approval of Enfortumab Vedotin Plus Pembrolizumab for Cisplatin-Ineligible MIBC

5 months ago

Christof Vulsteke, MD, PhD

1:09

AI-Powered Tools May Accelerate Developments in Precision Oncology for GI Cancer

5 months ago

William A. Hall, MD

0:50

Anderson Underscores Benefits of Daratumumab Combination in MRD-Postitive Multiple Myeloma

5 months ago

Larry Anderson, MD, PhD

Stephen Lam Chan, MBBS, MD (CUHK), FRCP,

1:04

RFS Outcomes With Adjuvant Pembrolizumab vs Placebo After Complete Radiological Response in HCC

5 months ago

Stephen Lam Chan, MBBS, MD

1:08

Hahn Highlights The Promise of Angiogenesis Targeted Therapies in RCC

5 months ago

Andrew W. Hahn, MD

0:21

Hirbe Previews Exciting Progress With Predictive Biomarker Research at SNO 2025

6 months ago

Angela C. Hirbe, MD, PhD

0:25

Schaff Spotlights Key Research in Leptomeningeal Metastases at SNO 2025

6 months ago

Lauren Shaff, MD

1:38

20th Annual New York Lung Cancers Symposium

7 months ago

Benjamin Herzberg, MD(+3 more)

0:57

Unpacking Data From the Phase 3 ROSELLA Study

7 months ago

Vanda Salutari, MD

0:32

The Significance of OptiTROP-Lung04 for TROP-2 ADCs in Lung Cancer

7 months ago

Pasi A. Jänne, MD, PhD

Video Shorts

Trending on OncLive

Vopimetostat Plus Daraxonrasib Yields 92% ORR in MTAP-Deleted, RAS-Mutant Pancreatic Cancer

KEYNOTE-D46 Trial Is Discontinued With Sacituzumab Govitecan Plus Pembrolizumab in PD-L1–High NSCLC

GU Cancer Experts Highlight the Most Impactful and Discussion-Worthy Data Presented at ASCO 2026

Subcutaneous Isatuximab Administered Via OBI Approved in EU for Multiple Myeloma

May’s GI Monthly Rewind: A Landmark Approval in CCA, Expanded Access for Daraxonrasib, and More Key Pipeline Updates